| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8780285 | Gynecologic Oncology | 2018 | 6 Pages |
Abstract
A comparison of PR for patients treated with PbCT for stage IV R0 and R1 disease suggested that a 1-year lag interval precedes clinical recognition of PbCT refractory/resistant R0 disease. Most patients treated with PbCT who had microscopic residuum had recurrences within 2Â years (across stages), emphasizing the need for more effective therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Lucia Tortorella, Carrie L. Langstraat, Amy L. Weaver, Michaela E. McGree, Jamie N. Bakkum-Gamez, Sean C. Dowdy, William A. Cliby, Gary L. Keeney, Mark E. Sherman, Saravut J. Weroha, Andrea Mariani, Karl C. Podratz,